After censoring the first 2 years of follow‐up, the meta‐analysis of study level estimates from the FHS and CHS indicated significant associations between baseline GFAP levels with incident all‐cause dementia (Fig. 3C HR = 2.06 [95% CI: 1.37–3.10], p < 0.001) and AD (Fig. 3D HR = 1.88 [95% CI: 1.29–2.73], p < 0.001). Here, GFAP is linked to Alzheimer disease.